symptoms. We report a 27-year-old multipara who underwent large loop excision of the transformation zone because of the repeated finding of a low-grade squamous intraepithelial lesion identified during routine cancer screening. Incidentally, CD20-positive, primary, diffuse large B-cell lymphoma infiltrating the mucosa of the endocervix
Novel Insights
• The case is unusual because the patient had no symptoms, specific colposcopic signs or visible mass.
• Cervical cytology has only a limited role in establishing the proper diagnosis, which can be best made on the basis of large loop excision of the transformation zone. Although the management of the reported patient deviated from standard gynecological cancer screening protocols, this led to reveal the hidden disease at an early stage.
• It is still unknown whether chemotherapy alone or in combination with radiotherapy or surgical intervention would be the optimal therapeutic approach. In this case, R-CHOP 21 immunochemotherapy was introduced and resulted in complete remission without hysterectomy.
Introduction
Primary non-Hodgkin lymphoma (NHL) involving the uterine cervix is extremely rare, with an incidence of 0.008% of all cervical tumors. Secondary involvement of the female genital tract as part of a systemic lymphoma is somewhat more common. Diffuse large B-cell lymphoma (DLBCL) represents a classical 'high-grade' NHL. Although this is one the most frequent lymphoid neoplasms of the cervix, its manifestation as a primary cervical tumor is considered a real rarity [1] [2] [3] [4] .
The standard treatment for systemic DLBCL patients was the administration of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). Since 1997, rituximab immunotherapy has been added to the CHOP regimen (R-CHOP) and has resulted in a significant improvement in the survival rate of these patients [5, 6] . Because of the low incidence of primary NHLs in the female genital tract (reflected by only scarce case reports) there is no wide enough multicenter experience regarding their best complex treatment. It is unknown whether chemotherapy alone or in combination with radiotherapy or surgical interventions such as hysterectomy, pelvic node dissection or salpingo-oophorectomy would be the optimal therapeutic approach to this group of diseases. Although R-CHOP could be considered the first-line regimen with promising results, a larger number of reported cases are needed to reach better-founded conclusions [1, 4, [7] [8] [9] .
The aim of the present case report is to document a rare clinical entity -a 27-year-old multipara incidentally diagnosed with DLBCL (WHO, CD20-positive) infiltrating the mucosa of the endocervix who was given R-CHOP therapy, responded well and is without evidence of disease after 49 months of follow-up.
Case Report
The patient's actual history started with a routine cancer screening 48 months after her second delivery at the Department of Obstetrics and Gynecology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
The cervical cytology (Pap smear) was interpreted as representing a low-grade squamous intraepithelial lesion (LSIL; cervical intraepithelial neoplasia grade 1, CIN 1) according to the Bethesda system. Colposcopic examination showed no specific signs and cytological features raised the possibility of chronic endocervicitis with human papillomavirus (HPV) infection. According to the recommendation of the cytopathologist in this case, repeated cervical cytology taken at 3-month intervals resulted in the finding of LSIL/CIN 1 again, with HPV negativity on the basis of HPV typing performed at an outside laboratory, and large loop excision of the transformation zone was performed. The cone was 6 mm deep, i.e. somewhat less than the 10 mm suggested for obtaining clear margins most of the time [10] . Histological results from the cone biopsy confirmed the presence of CIN I with koilocytic atypia and p16 immunohistological staining of the dysplastic cells suggestive of HPV infection and also established the diagnosis of DLBCL infiltrating the mucosa of the endocervix ( fig. 1 ). The CIN I lesion was present in 4 out of 9 histology blocks (the margins were either clear or not assessable), whereas the lymphoma involved 5 blocks and was almost exclusively present in the endocervical part of the biopsy -under the superficial glandular epithelium, around the glands (the margins being involved). The lymphoma cells were negative for cytokeratin and CD5 and stained positive for CD20 and MUM1, consistent with the activated B-like subtype of DLBCL. The Ki-67 labeling index of the tumor cells was estimated and reported 70%.
On physical examination, no spleno-or hepatomegaly was detected. Only some minimally enlarged lymph nodes, all smaller than 1 cm, were found inguinally on both sides. Although no detectable mass was found during initial colposcopy and physical examination, the pelvic MRI described an abnormal soft tissue mass measuring 6.5 × 2.3 × 1.5 cm between the uterine corpus and the bladder at the time of diagnosis. B signs were absent. Staging FDG-PET CT and pelvic MRI were performed and did not indicate any myometrial, nodal or other organ involvement. Thus, the patient's DLBCL was categorized as stage IE according to the Ann Arbor staging system. The international prognostic index was 0, and the Eastern Cooperative Oncology Group (ECOG) performance status was also 0.
After the proper diagnosis had been set up, six cycles of rituximab combined with standard CHOP chemotherapy (R-CHOP 21) were administered. In detail, the dosage was as follows: rituximab 375 mg/m 2 , cyclophosphamide 750 mg/m 2 and doxorubicin 50 mg/m 2 . Vincristine was given in a dose of 1.4 mg/m 2 on the 1st day of the cycles, and 100 mg of prednisone was also taken orally from the 1st to the 5th day of each cycle. The administered therapeutic regimen was planned according to the risk based on the ageadjusted international prognostic index. During the period of the treatment, there were no serious complications. The patient had reached partial remission 4 months after the introduction of the first cycle of R-CHOP 21 chemotherapy. The dimensions of the pelvic mass had significantly decreased and, as a consequence, the corpus of the uterus had become anteflected. At 3 months after the completion of R-CHOP 21 therapy, no circumscribed abnormal-ity could be identified between the corpus and the bladder on the pelvic MRI scan.
After the completion of immunochemotherapy, repeated cervical cytology was done. FDG-PET CT and pelvic MRI were also performed and confirmed the patient's complete remission (according to the Cheson criteria) [11] .
At 14 months after the completion of chemotherapy, the patient became pregnant spontaneously, but the pregnancy was miscarried due to unknown reasons on the 8th week. After 49 months of follow-up, the patient is without any evidence of disease.
Discussion
R-CHOP therapy of some subsets of NHL patients significantly improved their event-free and overall survival rates [5] . However, there are only limited data available on the R-CHOP immunochemotherapy of primary NHL of the female genital tract [7, 12, 13] . Vaginal bleeding is the most frequent primary symptom of genital lymphomas, but other symptoms such as abdominal pain or urinary complaints can also appear. The most common clinical finding is the presence of a vaginal, cervicovaginal or pelvic mass [8, 9, 14, 15] . The identification of the tumor is easier if colposcopy reveals a mass in the uterine cervix. For example, Binesh et al. [13] have reported a cervical mass identified by colposcopy, but no other lesions were detected in the case they described. When primary DLBCL appears without a bulky disease, the identification and the diagnosis of the tumor is more difficult. The present case was unusual in several respects, as no detectable mass or any other colposcopic lesions were identified. The patient had no vaginal bleeding or other symptoms which could have referred to the underlying lymphoma, which was a chance finding following further investigation of a cervical smear disclosing an LSIL. AlTalib et al. [16] have also reported a case of high-grade B-cell lymphoma of the uterine cervix. They discuss the cytology features and the differential diagnosis with emphasis, not just on the importance of the cervical biopsy but on also the potential role of the cervical smear in the initial diagnosis of this tumor. Grace et al. [3] highlight the difficulty of diagnosing cervical lymphoma in the 2 cases they present, and suggest that cervical biopsy is needed to establish the diagnosis.
In line with previous reports, it can be concluded that vaginal bleeding and a mass in the uterine cervix can be the first signs of the disease in most cases but, as our case report shows, there may be exceptions too [8, 17] . Cervical lymphomas are initially subepithelial and, therefore, there is a danger of underdiagnosis with cervical cytology, especially in the early stages. Cytology is unlikely to detect NHL, unless the disease has progressed to the epithelium, and biopsy is generally required to establish the proper diagnosis, as in the present case, where a coexisting LSIL initiated the biopsy. Based on previously reported cases, primary DLBCL of the female genital tract can occur at any age. With the introduction of immunochemotherapy, we could hope for a promising result regarding disease-free survival, but this introduces another important challenge -how to preserve the childbearing potential [1, 18, 19] . There are only limited data on the recommended time of contraception, the risk of miscarriages or the pregnancy outcome of women with and after R-CHOP immunochemotherapy in primary NHL of the female genital tract [1, 18, 19] .
There are some data indicating that CHOP chemotherapy may be given safely to NHL patients in the third trimester of pregnancy [18] . Lorusso et al. [1] have reported a 29-year-old woman who was treated with neoadjuvant chemotherapy and conservative surgery for a primary stage IE NHL of the uterine cervix in whom pregnancy was possible 3 years after the primary treatment, and the patient successfully delivered a full-term healthy infant. In contrast, our patient had become spontaneously pregnant 14 months after chemotherapy but experienced missed abortion. It can be speculated that previous chemotherapy had an influence on the termination of pregnancy, but the opposite may also hold true.
Conclusion
Primary cervical lymphomas are initially localized and subepithelial. Therefore, cervical cytology has only a limited role in establishing the proper diagnosis, which can be best made on the basis of large loop excision of the transformation zone. Although in this case the patient's management deviated from standard gynecological cancer screening protocols, this led to reveal the hidden disease at an early stage, and this chance finding led to further treatments which can contribute to the widening experience in the treatment of organ-specific, localized NHLs in the female genital tract. In terms of therapy, our case report supports the notion that R-CHOP can be considered as a first-line regimen, with promising results in these rare manifestations of DLBCL. The interest in the case lies not only in its rarity but also in the fact that our patient recovered from the disease without hysterectomy.
